Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2011
01/11/2011US7868160 Compositions and methods for inhibiting expression of anti-apoptotic genes
01/11/2011US7868047 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
01/11/2011US7868045 Method for promoting gastrointestinal bicarbonate secretion
01/11/2011US7868044 FDA Orange book listed patent for adapalene (title compound); topical treatment using aqueous gels, creams, lotions or solutions with at least one polymeric emulsifier, modified cellulose, gum, starch, biopolymer or alginate; better therapeutic efficacy and good tolerance
01/11/2011US7868043 Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
01/11/2011US7868042 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; for improving renal function; nitric oxide synthase modulators; hypotensive agents
01/11/2011US7868041 prodrugs of gabapentin and pregabalin, such as 2-[1-[[[(2R)-6-oxooxan-2-yl]oxycarbonylamino]methyl]cyclohexyl]aceticacid, used for for treating epilepsy, depression, anxiety, psychosis, brain disorders, neurodegenerative diseases, pain, inflammatory disease, gastrointestinal disorders or drug abuse
01/11/2011US7868040 Anti-cancer combinations
01/11/2011US7868039 Anti-cancer combinations
01/11/2011US7868038 Compounds as cannabinoid receptor ligands
01/11/2011US7868037 comprising administering compounds that affect viral internal ribosome entry site (IRES) activity, such as [4-(3-cyano-1-ethyl-6-methoxy-1H-indol-2-yl)-phenyl]-carbamic acid ethyl ester
01/11/2011US7868036 Renin inhibitors; hypertension, heart failure, glaucoma, myocardial infarction, kidney failure or restenosis; broad group of compounds that are hydroxy-functional diamines such as 3-Amino-1-isopropylamino-5-[3-(3-methoxypropyl)-1-methyl-1H-indol-5-ylmethyl]-6-methylheptan-2-ol dihydrochloride
01/11/2011US7868035 such as [3-(2-aminoethyl)-1H-indol-5-yl](Z)-7-[(1R,2R,3R,5S)-2-[(E,3S)-5-(4-bromo-5-methylthiophen-2-yl)-3-methoxypent-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate, used for the treatment of vision defects
01/11/2011US7868034 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
01/11/2011US7868033 benzoxazoles derivatives such as 2-(4-Trifluoromethoxy-phenyl)-benzooxazole-5-carboxylic acid, used for the treatment of Alzheimer's disease, spongiform encephalopathy, polyneuropathy, cardiomyopathy, non-insulin dependent diabetes and medullary carcinoma of the thyroid
01/11/2011US7868032 Such as [1S-(1 alpha, 2 alpha, 3 alpha, 4 alpha)]-2-[[3-[[(4-cyclohexylbutyl)-amino]-carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-1-[[(ethylamino)-carbonyl]methoxy]-4-fluorobenzene; prostaglandins; drug screening; hirsutism; arthritis
01/11/2011US7868031 Propionamide compounds as antiinflammatory agents
01/11/2011US7868030 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents
01/11/2011US7868029 Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates
01/11/2011US7868028 blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants
01/11/2011US7868027 Process for the preparation of certain substituted sulfilimines
01/11/2011US7868026 Therapeutic compounds
01/11/2011US7868024 vanilloid receptor antagonists such as N-(1,2-Dimethyl-1H-benzimidazol-5-yl)-5-fluoro-1-(4,6-dimethylpyridin-2-yl)-1H-indole-2-carboxamide, used for the treatment of inflammation, psoriasis, pruritus, herpes, shingles, multiple sclerosis, metabolic, gastrointestinal and respiratory system disorders
01/11/2011US7868023 4-[(3-Bromophenyl)-N-{3-(5-methyl-[1,3,4]oxadiazol-2-yl)-benzene-sulfonyl}sulfoxamino]-5-methylsulfanyl-thiophene-2-carboxamidine trifluoroacetate;
01/11/2011US7868022 Drug for Alzheimer's disease; cognition activators; strokes; down's disease; Parkinson's disease
01/11/2011US7868021 Antimicrobial quinolones, their compositions and uses
01/11/2011US7868020 Quinolynylmethylimidizoles as therapeutic agents
01/11/2011US7868019 applying a pyridine compound such as 1-[2-(1,2-dihydro-3-morpholino-2-oxoquinolin-1-yl)pyridin-4-yl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene, for the treatment of skin disorders; dermatitis, psoriasis or eczema
01/11/2011US7868018 such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders
01/11/2011US7868017 Monoamine reuptake inhibitors such as exo-3-(benzo[d]isothiazol-7-yloxy)-9-azabicyclo[3.3.1]nonane, used as antidepressants, anxiolytic agents and analgesics, or for the treatment of obsessive compulsive disorder
01/11/2011US7868016 Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
01/11/2011US7868015 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
01/11/2011US7868014 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
01/11/2011US7868013 Cycloalkyl substituted pyrimidinediamine compounds and their uses
01/11/2011US7868012 3-hydroxypropylsulfamic acid {5-(4-bromophenyl)-6-[2-(5-bromoprimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide, used for treatment of hypertension, congestive heart failure, renal and myocardial ischemia, renal failure, ischemia, dementia, headaches, hemorrhage, Raynaud's syndrome and ulcers
01/11/2011US7868011 Hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant; kits
01/11/2011US7868010 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; absorbed less rapidly from mucosal surfaces, less reversible
01/11/2011US7868009 (5R)-5-{2-[4-(4-Fluorophenyl)piperazin-1-yl]-2-oxoethyl}-2,2-dimethyl-1,3-dioxolan-4-one; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis
01/11/2011US7868008 Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
01/11/2011US7868007 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
01/11/2011US7868006 chemokine receptor antagonists used for the therapy of inflammatory diseases, autoimmune diseases, transplant rejection, infectious diseases, ophthalmic inflammation, diabetes, meningitis, tumors and side effect reduction
01/11/2011US7868005 Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
01/11/2011US7868004 when applied to the skin or mouth in the form of orally ingestible foods or beverages, tobacco products, creams, ointments, sprays, mouthwashes, dentifrice or toiletries; N-4-(pyrazol-1-yl)-phenyl-3-p-menthanecarboxamide
01/11/2011US7868003 Substituted 4-phenyltetrahydroisoquinolines, pharmaceutical compositions comprising them and therapeutic methods for their use
01/11/2011US7868002 Deazapurines and uses thereof
01/11/2011US7868001 such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer
01/11/2011US7868000 Aspartyl protease inhibitors
01/11/2011US7867999 Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
01/11/2011US7867998 administering plant extracts isolated from Radix Stemonae selected form croomine, 6-hydroxycroomine, stemospironine, 10-hydroxycroomine, stemoninine and tuberostemoamide, as antitussive agents
01/11/2011US7867997 δ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
01/11/2011US7867996 a crystal stuctured form of 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one hydrochloride, useful as bradycardial agents
01/11/2011US7867995 βd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
01/11/2011US7867994 reacting 3-[2-(1,3-dioxolan-2-yl)ethyl]-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, with 7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N-methylmethanamine hydrochloride, in the presence of hydrogen and palladium supported on carbon, to give ivabradine hydrochloride; bradycardial agents
01/11/2011US7867993 Preparation containing oxidized flavonoid derivatives
01/11/2011US7867992 such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses
01/11/2011US7867991 Hypertension and dyslipidemia combination therapy using compounds that are both Angiotensin II 1 receptor antagonists, and activators of peroxisome proliferator activated receptors (PPARs), and antilipemic agents such as statins; telmisartan and simvastatin for example
01/11/2011US7867990 Steroid hormone products and methods for preparing them
01/11/2011US7867989 α-glucosidase inhibitors from lichens
01/11/2011US7867988 Macrocyclic lactone compounds and methods for their use
01/11/2011US7867986 Enhanced drug delivery in transdermal systems
01/11/2011US7867985 Injection of a synthetic synovial fluid containing one or more phosphatides, such as dipalmitoyl phosphatidylcholine, and a biodegradable dextran-glycidyl methacrylate copolymer hydrogel; phosphatides are incorporated into the cartilage of the arthritic, injured, or diseased joint; antiarthritic agents
01/11/2011US7867983 Methods to protect skeletal muscle against injury
01/11/2011US7867981 Compositions comprising highly purified amphotericin B
01/11/2011US7867980 Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient
01/11/2011US7867979 Combination of mangiferin and berberine has a preferable hypoglycemic and hypolipidemic effect compared with mangiferin and berberine which is used alone; bioavailability, low cost, low toxicity
01/11/2011US7867949 Hydrazide compound and pesticidal use of the same
01/11/2011US7867527 synergistically reduces dark melanin production
01/11/2011US7867523 Pharmaceutical composition
01/11/2011US7867517 Oral pharmaceutical composition with improved bioavailability
01/11/2011US7867516 Tablet with masked odor or bitterness; especially with a photostabilizer
01/11/2011US7867511 Abuse potential reduction in abusable substance dosage form
01/11/2011US7867509 Fast dissolving orally consumable films
01/11/2011US7867508 administering a decongestant(oxymetazoline hydrochloride), a corticosteroid (triamcinolone acetate) and anticholinergic agent ipratropium bromide for nonaddictive treatment of upper respiratory conditions in man and animals, e.g., allergic, non-allergic and mixed rhinitis in man or pharyngitis in horses
01/11/2011US7867217 System with a reservoir for perfusion management
01/11/2011CA2690824C Methadone formulation
01/11/2011CA2631068C Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts
01/11/2011CA2577310C Methods and compositions for oral delivery of fts
01/11/2011CA2575777C Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives
01/11/2011CA2566922C Stable crystal of 4-oxoquinoline compound
01/11/2011CA2545052C Method for the catalytic production of hydrocodone and hydromorphone
01/11/2011CA2536384C Cyclic derivatives as modulators of chemokine receptor activity
01/11/2011CA2534088C 2,3-substituted pryidl compounds useful for treating pain
01/11/2011CA2518740C Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
01/11/2011CA2503371C Quinazoline derivatives as src tyrosine kinase inhibitors
01/11/2011CA2495455C Use of i.kappa.b-kinase inhibitors in pain therapy
01/11/2011CA2492138C N-phenyl-(2r,5s)dimethylpiperazine derivative
01/11/2011CA2487973C Method for preparing 1,3,5-triaminobenzene and hydrolyzing it into high-purity phloroglucinol
01/11/2011CA2487590C Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof
01/11/2011CA2472149C New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments
01/11/2011CA2469876C Benzothiazoles
01/11/2011CA2468824C Hexacyclic compounds
01/11/2011CA2462390C Anthranilic acid amides and pharmaceutical use thereof
01/11/2011CA2461623C Water-in-oil emulsions with ethylene oxide groups, compostions, and methods
01/11/2011CA2460696C Use of substituted aminomethyl chromans for the treatment of extrapyramidal movement disorders
01/11/2011CA2456426C New mandelic acid derivatives and their use as thrombin inhibitors
01/11/2011CA2453996C Injectable pharmaceutical formulations
01/11/2011CA2453974C 4-(benzylideneamino)-3-(methylsulfanyl)-4h-1,2,4-triazin-5-one derivatives having a pde iv-inhibiting and tnf-antagonistic action for the treatment of heart diseases and allergies
01/11/2011CA2453445C Pyridin-2-yl-methlyamine derivatives for treating opioid dependence
01/11/2011CA2451678C Azaindoles
01/11/2011CA2448242C Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain